Title & Introduction

  • Paper Title: Development of an Australian Clinical Practice Guideline on MDMA-Assisted Psychotherapy for Post-Traumatic Stress Disorder
  • Published In: medRxiv (Preprint)
  • Publish Date: February 21, 2025
  • Authors: Alene Sze Jing Yong, Sue E. Brennan, Suzie Bratuskins, Aimée Freeburn, Gillinder Bedi, Rimona Burke, Terry Haines, Mary Hollick, Kimberley Ann Jones, Andrew J. Lawrence, Yong Yi Lee, Alexander C. McFarlane, Stephen Parker, Nicholas Procter, Liam Spicer, Andrew A. Somogyi, Simon Stafrace, Stacey Watts, Clare Walton, Kay Wilson, J. Simon Bell
  • Objective: To develop an evidence-based clinical practice guideline for the use of MDMA-assisted psychotherapy (MDMA-AP) for post-traumatic stress disorder (PTSD) in Australia.
  • Importance: The rescheduling of MDMA in Australia has created an urgent need for standardized guidelines to ensure safe and effective use in clinical settings.

Summary & Takeaways

Key Takeaway: The guideline will provide evidence-based recommendations for the safe and effective administration of MDMA-assisted psychotherapy for PTSD, ensuring regulatory compliance and clinical best practices.

Practical Application:
This guideline will serve as a reference for psychiatrists and healthcare providers in Australia to ensure safe, standardized, and ethically responsible administration of MDMA-assisted therapy for PTSD patients.

Key Background Information

  • Context: In July 2023, the Australian Therapeutic Goods Administration rescheduled MDMA, allowing authorized psychiatrists to prescribe it for PTSD outside of clinical trials. However, there is no existing clinical guideline to govern its use.
  • Hypothesis: A structured clinical guideline can facilitate the safe and effective integration of MDMA-AP into psychiatric practice, addressing both benefits and potential harms.

Methodology

  • Study Design: Development of a clinical practice guideline using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework.
  • Participants: Guideline Development Group (GDG), comprising clinicians, researchers, regulatory experts, and consumer representatives.
  • Intervention/Exposure: Review of systematic studies, stakeholder consultations, and expert analyses on MDMA-AP for PTSD.
  • Controls: Not applicable.
  • Duration: The guideline development began in early 2024 and is expected to be published by 2025.

Key Findings

Primary Outcomes:

  • The guideline will evaluate MDMA-AP’s benefits and harms, incorporating findings from systematic reviews and meta-analyses.
  • The framework includes considerations of patient safety, risk management, and standardized treatment protocols.
  • The guideline will include recommendations for training and certification requirements for practitioners.
  • It will incorporate Indigenous and culturally sensitive perspectives on trauma-informed care.
  • The guideline will be hosted on the MAGICapp digital platform for accessibility.

Secondary Outcomes:

  • Stakeholder groups, including government agencies, professional bodies, and patient advocacy organizations, support the need for clear clinical guidance.
  • There is a need for further empirical data to address concerns about MDMA-AP’s long-term safety and potential for misuse.
  • Ethical considerations, including informed consent and patient monitoring, will be emphasized in the final guideline.

Interpretation & Implications

  • Conclusion: The guideline will help psychiatrists implement MDMA-AP responsibly, mitigating risks while maximizing therapeutic benefits.
  • Implications: The structured approach outlined in the guideline can serve as a model for other jurisdictions considering MDMA-assisted therapy.
  • Limitations: This is a preprint document and has not yet been peer-reviewed. The guideline’s effectiveness will need to be evaluated through real-world clinical application.

Researchers & Publication

  • Researchers: Alene Sze Jing Yong, Sue E. Brennan, Suzie Bratuskins, Aimée Freeburn, Gillinder Bedi, Rimona Burke, Terry Haines, Mary Hollick, Kimberley Ann Jones, Andrew J. Lawrence, Yong Yi Lee, Alexander C. McFarlane, Stephen Parker, Nicholas Procter, Liam Spicer, Andrew A. Somogyi, Simon Stafrace, Stacey Watts, Clare Walton, Kay Wilson, J. Simon Bell
  • Publication Name: medRxiv (Preprint)
  • Study URL: https://doi.org/10.1101/2025.02.18.25322184
Share this post